Recruiting OBSERVATIONAL NCT05286138

STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY (Tum001)

STUDY MULTICENRIC OBSERVATIONAL, NO-PROFIT FOR THE INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY

Sponsor: Società Italiana Talassemie ed Emoglobinopatie

Conditions Malignacy, Hemoglobinopathie

Updated 4 times since 2022 Last updated: Mar 18, 2022 Started: Feb 1, 2022 Primary completion: Feb 28, 2024 Completion: Feb 28, 2052

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Malignacy, Hemoglobinopathie and is currently actively recruiting participants. Società Italiana Talassemie ed Emoglobinopatie leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
May 2022 — Jul 2024 [monthly]

Recruiting
Apr 2022 — May 2022 [monthly]

Recruiting

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Società Italiana Talassemie ed Emoglobinopatie

Data source: Società Italiana Talassemie ed Emoglobinopatie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cagliari, Italy